PortugalPortugal

Bleak outlook for western Iberia

11.08.2011

Lisbon – According to a report published by business intelligence provider Espicom, the future for biopharma on the westernmost tip of Europe looks anything but sunny. Its analysts predict that by 2016, the pharmaceuticals market in Portugal will rank as one of the smallest in Western Europe – in a dismal 14th place. In per capita terms, Portugal will have very low expenditure, while generic growth is expected to slow down in the medium-term. This will boost the generic penetration of the market and skewer the uptake of innovative and expensive biotech drugs, says the report. From 2011-2016, Espicom predicts sluggish sales growth due to expected cost-containment measures. In 2010, the cash-strapped Portuguese government slashed prices twice, bringing the cumulative price cut to nearly 15% in less than a single year.

PortugalPortugal

19.08.2008

Lisbon – The international contract research organisation Chiltern sees potential for growth in Portugal. In May, it opened a new office in Lisbon that will be managed by Ricardo Diaz. Over the last two years, numbers of clinical...

PortugalPortugal

19.03.2008

Porto – 164 farmers planted a total of 4,199 hectares of genetically modified maize in Portugal in 2007, according to a report issued by the Portuguese Ministry of Agriculture. That represents a 330% increase compared to 2006,...

PortugalPortugal

22.11.2007

Cantanhede – Biogen Idec (Cambridge, US) and the Portuguese biopark Biocant in the Coimbra region have signed a socalled ‘Sponsored Research Agreement’ worth an undisclosed amount. Under the terms of the agreement, researchers...

Portugal, SpainPortugal

11.07.2007

Oeiras/Navarra – Portuguese antibody and genomics specialist Biotecnol SA and the Spanish university spin-off Digna Biotech will develop a process for manufacturing cardiotrophin-1 (CT-1) for the treatment of ischemic-reperfusion...

PortugalPortugal

11.07.2007

Porto – In September 2005, the Portuguese government established a decree law (No. 160/2005) on the co-existence between genetically modified organisms (GMO), conventional and organic crops. In short, it recommends a minimum...

PortugalPortugal

11.07.2007

Almada – transADVANcis Lda, a consultancy firm for nanotechnology and life sciences executives, has launched a website called www.nanogolive.com. With the new portal, on which anyone from the nanotechnology and life science...

PortugalPortugal

16.05.2007

Porto – Two Portuguese biotech companies have won the national idea contest for bio-entrepreneurs (Concurso de Ideias Bioempreendedor 2006), organized every year by the Portuguese Association of Bioindustries (APBio) and the...

PortugalPortugal

16.03.2007

Port Salvo – Biotrend S.A., developers of high-value compounds based in Lisbon, has closed a second investment round with the public venture capital outfit PME Investimientos, ending with a total investment exceeding 1 million...

PortugalPortugal

16.03.2007

Porto Salvo – Alfama, developers of small molecule drugs, has opened a laboratory in Boston, Massachusetts, in order to achieve US presence. The company will carry out research on the effects of self-developed molecules on...

Italy, PortugalPortugal

16.09.2006

Milan/Sintra – The Italian pharmaceutical company Recordati S.p.A agreed in July to acquire Jaba Farmacêutica (Sintra, Portugal) and all other pharmaceutical businesses belonging to the Grupo Jaba in Portugal. The purchase price...

Displaying results 11 to 20 out of 37

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-portugal/browse/1/article/bleak-outlook-for-western-iberia.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THROMBOGENICS (B)9.54 EUR-5.07%

TOP

  • WILEX (D)3.15 EUR314.5%
  • SANTHERA (CH)68.55 CHF90.4%
  • ADDEX (CH)4.08 CHF82.1%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.77 EUR-29.2%
  • PROSENSA (NL)9.81 USD-22.6%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP729.1%
  • PAION (D)2.79 EUR316.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.5%

No liability assumed, Date: 25.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products